Predicting allergic reactions
AssigneeAlcyomics LTD
InventorAnne Dickinson
Life of this patent
Estimating the term…
Abstract
This present invention provides a method of predicting immunogenicity and hypersensitivity or allergic reactions to chemical compounds, therapeutics, cosmetics and other chemical compositions. The method uses an in vitro assay employing autologous blood derived cells and an autologous cultured skin biopsy and is of particular utility in the identification and prediction of skin sensitizers that cause allergic contact dermatitis.
Claims8
1-22. (canceled)
An in vitro method for identifying antibodies that are sensitizers or non-sensitizers, the method comprising
- (i) incubating a population of peripheral blood mononuclear cells isolated from a donor blood sample with a test antibody;
- (ii) incubating the antibody treated peripheral blood mononuclear cells of (i) with a skin biopsy sample obtained from the same donor;
- and
- (iii) assessing hypersensitivity and allergic reactions by graded histological changes in the treated skin biopsy sample of (ii) as compared to a control, wherein a graded histological change of II or greater in the skin biopsy sample as compared to control identifies the test antibody as a skin sensitizer and/or allergen in said subject.
An in vitro method for determining the potency of an antibody, the method comprising
- (i) incubating a population of peripheral blood mononuclear cells isolated from a donor blood sample with a test antibody;
- (ii) incubating the antibody treated peripheral blood mononuclear cells of (i) with a skin biopsy sample obtained from the same donor;
- and
- (iii) assessing potency by graded histological changes in the treated skin biopsy sample of (ii) as compared to a control, wherein a graded histological change in the skin biopsy sample compared to control corresponds to a defined potency index and determines the potency of the test component.
Dependencies are inferred from the claim text.